On ECHEMI
Home > Drugs > Camurati-Engelmann disease
Camurati-Engelmann disease
Progressive diaphysial dysplasia (PDD) is also known as proliferative periostitis, symmetrical sclerosing pachyostosis, Engelmann disease or Camurati-Engelmann disease. The disease is named after Camurati (1922) and Engelmann (1927) reported respectively, and is an autosomal dominant bone disease. The disease is characterized by systemic symmetrical bone development abnormalities, manifested as abnormal proliferation of the inner and outer periosteum of long bones, resulting in thickening of the bone cortex, thickening of the bone shaft and narrowing of the medullary cavity. On the basis of bone sclerosis, patchy areas of reduced bone density can be seen. The epiphysis is generally normal, but it can also be affected, so some people advocate calling PDD progressive diaphysis-epiphyseal dysplasia. Involvement of long bones can cause movement disorders and bone pain in patients. Skull sclerosis can lead to hearing loss and smell loss or loss.
  • Site of disease:

    bone
  • Infectious :

    Not contagious
  • Frequent population:

    Infants and young children
  • Related symptoms:

    Unsteady gait Visual impairment Increased intracranial pressure Muscle atrophy Ataxia
  • Concurrent disease:

Related Drugs
Decitabine for injection
Indication: It is suitable for the first-time and retreatment of intermediate-2 and high-risk myelodysplastic syndrome (MDS) in the IPSS scoring system, including primary and secondary MDS, and all subtypes according to the FAB classification.
Manufacturer:

Zhengda Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.